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ABSTRACT
Alzheimer’s disease (AD) is a complex neurodegenerative disease that is characterized by the
deposition of amyloid beta (A) peptides and, consecutively, by a loss of memory and cognitive
functions. The amyloid cascade hypothesis suggests that A deposition is the main pathogenic of
AD. There is evidence that both changes in production and clearance of A may be involved in
AD pathology. Past studies have shown that exercise training leads to an upregulation in proteins
directly involved with A clearance. Chronic stress is thought to exacerbate AD pathology by
increasing production of A. Studies have also demonstrated a link between serotonin signaling
and decreased A production. Although these factors affecting AD pathology have each been
investigated, the interplay between all three has yet to be evaluated. This study aimed to examine
the effects of chronic stress and exercise training on both A levels, as well as serotonin
signaling. APP/PS1 mice were divided into housing and exercise groups: sedentary and isolated,
sedentary and socially housed, exercise trained and isolated, and exercise trained and socially
housed. Mice were also divided based on sex. Due to the COVID-19 pandemic not all goals of
this project were met. The results demonstrate that exercise training may be able to rescue the
negative effects of isolation on A deposition; however, a training effect was not produced in the
exercise trained groups, so the trends of this research may need to be reevaluated.
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LITERATURE REVIEW

Overview of Alzheimer’s Disease
Alzheimer’s disease (AD) is a neurodegenerative disease that effects millions in the
United States, making it the most prevalent form of dementia. Most common in the elderly, ages
65 and older, AD has hallmark symptoms of memory defectiveness and language impairment.
The brain changes associated with AD, that lead to cognitive issues, can begin 20 years prior to
noticeable symptoms. There are three stages of AD: preclinical AD, mild cognitive impairment
(MCI) and dementia (Jack et al., 2011; Albert et al., 2011; McKhann et al., 2011).
In preclinical AD, no symptoms are present, but brain changes have already begun, such
as an increased in the A peptide (Alzheimer’s Disease Facts and Figures, 2019). Preclinical AD
typically goes unnoticed, as people do not routinely check for upregulation of AD associated
biomarkers without cognitive impairment.
For someone suffering from MCI, symptoms of cognitive decline are present and are
greater than expected for that person’s age range. Although symptoms are present, the change in
cognitive function is not detrimental enough to interfere with everyday life. Close to 20% of
people over the age of 65 have MCI (Roberts & Knopman, 2013) Five years after MCI
diagnosis, 38% of people had developed dementia (Mitchell & Shiri-Feshki, 2009). Considering
AD is most common in the elderly population, it can be difficult to distinguish between agerelated changes and MCI. For instance, while forgetting names and appointments is pretty
common, forgetting the same thing numerous times can be indicative of MCI. Also, excessive
reliance on memory aids, like notes or phone apps, can be indicative of MCI. Other common
symptoms at this stage include: finding problem solving more difficult, confusion in time or
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place, withdrawal from social settings, as well as changes in mood and personality (Alzheimer’s
Disease Facts and Figures, 2019).
As memory and behavioral symptoms begin to interfere with daily life, and there is clear
evidence of brain related changes MCI becomes AD. Symptoms can worsen over time in
dementia or change completely. There are three sublevels within AD pathology mild, moderate
and severe (Alzheimer’s Disease Facts and Figures, 2019). With mild dementia, people typically
remain independent, but require help in with certain tasks, like organizing medicine. Normally,
people at this stage maintain the ability to participate in their favorite activities, drive and do
everyday housework. Once AD progresses into the moderate stage, the ability of the patient to
live independently decreases. This stage typically lasts the longest. The ability to communicate
tends to decline with moderate dementia due to AD. Specifically, patients may have difficulty
bathing and dressing. Patients may also become intermittently incontinent. Late in the
progression of moderate dementia, personality and behavioral changes can occur, including
suspiciousness of one’s caretakers and doctors (Alzheimer’s Disease Facts and Figures, 2019).
For patients with severe dementia, constant care is typically required, and the patient may even
become bed-bound leading to many hardships, including, vulnerability to sepsis and skin
infections. It is not uncommon, for these patients to experience some damage in brain regions
that control swallowing, increasing the risk for aspiration of food. Aspiration pneumonia is one
of the main causes of death associated with AD (Alzheimer’s Disease Facts and Figures, 2019).
Diagnosis and Treatment. Alzheimer’s disease can be difficult to diagnose. Instead of
using AD biomarker testing, due to issues with availability and reliability, many doctors rely on
family medical and psychological histories, family input about cognitive function, cognitive tests
and physical examinations, and blood tests to rule out other forms of dementia, like certain
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vitamin deficiencies. Even after being diagnosed, there is not much help therapeutically for AD.
Currently, five drugs are available for the treatment of AD and have been approved by the U.S.
Food and Drug Administration (FDA): rivastigmine, donepezil, memantine, galantamine, and a
combination of donepezil and memantine (Alzheimer’s Disease Facts and Figures, 2019). Like
many neuroactive medications, the effectiveness of these drugs varies between people.
Although there are not many drugs on the market to aid those with AD, and no drugs to
prevent or cure AD, there are many non-pharmacological tactics that help improve AD
symptoms. The main therapies are cognitive stimulation and exercise. Cognitive stimulation has
favorable effects on cognition, but did not affect mood, or the ability to perform normal daily
activities (reviewed in Aguirre et al., 2013).
Exercise, both aerobic and non-aerobic, has a demonstrated positive effect on cognition,
and may also slow the rate of cognitive decline in AD patients. However, there are many
variables that make it hard to fully assess exercises effect on AD pathology, including length and
intensity of exercise. In mice, downregulation of A have been seen following moderate
intensity exercise training regimens (Moore et al., 2016).
Prevalence and Incidence. There are 5.8 million Americans living with AD, and 5.6
million of those are age 65 years or older (Hebert et al., 2013). Age seems to be the biggest risk
factor for AD, as 81% of people suffering from dementia due to AD are 75 or older (Figure 1).
Although the number of cases of AD is already extremely high, it is likely not quite high
enough due to the obstacles faced during diagnosis. In the coming years, the number of people
afflicted by AD will presumably skyrocket, as the number of people age 65 and older, in
America, is expected to grow from 55 million now to 88 million in 2050 (He et al., 2016; US
Census Bureau, 2014). Although the incidence of AD is debated between studies, normally
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somewhere between 500,00 and 910,000 people develop AD in the US per year (Rajan et al.,
2019). By 2025, a 12% increase in AD cases throughout the US is expected (Weuve et al., 2015).

Sex Disparities. Two-thirds of Americans afflicted with AD are women (Hebert et al.,
2013). There is not sufficient evidence to determine whether this discrepancy between men and
women is due to a typically longer life (longevity hypothesis), or due to differences in molecular
pathways between the sexes (Carter et al., 2012). The longevity hypothesis proposes that females
only seem more affected because on average women live longer than men (Chene et al., 2015;
Seshadri et al., 1997; Hebert et al., 2001). Survival bias is also a factor, because only the
healthiest men that do live to older ages, reducing the risk for AD development. However, there
are variations in mechanisms between men and women when it comes to AD, which could lead
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to different risk levels. For example, women respond differently to chronic stressors than men
(Yan et al., 2018).
Ethnic Disparities. Racial and ethnic differences appear to play a role in the risk of
developing AD. African-Americans are twice as likely to be afflicted compared to Caucasians of
the same age (Potter et al., 2009; Gurland et al., 1999). Hispanics are 1.5 times as likely to
develop AD compared to Caucasians (Gurland et al., 1999; Haan et al., 2003; Samper-Ternent et
al., 2012). However, Asian Americans have the lowest risk of being afflicted (Mayeda et al.,
2016). It remains unclear why these discrepancies are seen. They are often attributed to increased
exposure of many minorities to AD risk factors like, poverty, lower levels of education, and
increased stress due to adversity and discrimination (Lines et al., 2014; Glymour & Manly, 2008;
Zhang et al., 2016).
Deadliness of AD. Being the sixth-leading cause of death, AD was responsible for
121,404 deaths in the 2017 (Heron, 2018; US Department of Health and Human Services, 19992017). For those over the age of 65, AD was the fifth-leading cause of death (Heron, 2018). In
addition to being a top cause of death, AD is also a leading cause of disability and morbidity.
Deaths due to AD might be even higher than currently reported because many deaths are
attributed to acute conditions that are actually just a side effect of the underlying AD (Ives et al.,
2009; Romero et al., 2014). For example, pneumonia is listed as the cause of death for many
afflicted by AD, but, as noted previously, pneumonia may be caused by aspiration of food due to
impaired swallowing in AD. Whether it is listed as the cause of death, or is linked to a patient’s
death, those with AD have significantly increased mortality. Specifically, among 70-year old’s,
61% with AD, whereas only 30% of those without AD, are not expected to reach 80 years of age
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(Arrighi et al., 2010). As the mean age of the population in America rises, AD is becoming an
increasingly common cause of death.
AD is a debilitating disease that effects millions (Alzheimer’s Disease Facts and Figures,
2019). At first, AD might be comparable to age related cognitive changes, like increased
forgetfulness, but with time, AD patients lose their independence and require continually care.
AD is not only detrimental to those afflicted, but also to families and caregivers.

Amyloid Beta Production and Clearance
APP Overview. Amyloid precursor protein (APP) is a member of a type 1 membrane
protein family including APLP1 and APLP2 (Wasco et al., 1993). The entire mammalian APP
family has a conserved structure including a large ectodomain, a single transmembrane domain
and one internal domain (Figure 2).
The ectodomain is responsible for substrate adhesion and seems to have a neurotrophic
effect (Small et al., 1994). It has two regions, E1 and E2. E1 is most distal from the membrane,
and includes two subunits; the heparin binding domain (HBD) and the copper/metal binding
domain. Within the HBD there is a loop compromised of mostly basic amino acids, to which
heparin can bind (Small et al., 1994). Heparin is a naturally occurring anticoagulant, and possibly
has some anti-inflammatory effects (reviewed in Oduah et al., 2016). The E2 region contains the
active component of APP, the amino acid sequence “RERMS”, as well as many -helices that
can easily dimerize with other APP proteins (Xue et al., 2011). This indicates that the E2
domain plays a role in self-association of APP, which can aid in cell adhesion and
communication, as well as regulate APP processing. The A sequence begins in close proximity
to the membrane, and it continues into the transmembrane domain (Figure 2). The APP
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intracellular domain (AICD) is highly conserved and important to modulating APP function. The
AICD is 47 amino acids in length and contains the “YENPTY” motif which is a C-terminal
endocytic signal (Lai et al., 1995). The AICD plays a role in APP localization, metabolism and
cell signaling.

E1

E2
β
α
γ

Cellular Membrane

TMD

AICD

Figure 2. APP structure and enzymatic processing sites.

The APP gene is found on the long arm chromosome 21 and contains 18 exons (Yoshikai
et al., 1990). Due to alternative splicing there are numerous isoforms of APP varying from 365
amino acids to 770 aa. The main, A producing, isoforms are APP695, APP751 and APP770.
7

Certain alternative splicing sites seem to be favored based on the tissue, as APP695 is found
almost exclusively in neurons (Kang et al., 1987). APP770 and APP751 are present in astrocytes
and microglial cells (Rohan de Silva et al., 1997).
The exact function of APP has not yet been discovered, but there is strong evidence that
APP plays a role in many critical biological functions. The APP gene is a housekeeping gene,
meaning that it is continuously expressed and required for essential cellular functioning
(Salbaum et al., 1988). A number of transcription factors that regulate cell proliferation and
mitosis genes also have a regulatory role for APP transcription (Salbaum et al., 1988). This
suggests that APP may also have a role in cell growth. This is supported by data demonstrating
an increase in APP during times of development and growth (Clarris et al., 1995).
Many studies using APP-KO mice, have demonstrated that mice lacking the APP gene
are still viable and fertile, but are smaller in stature, have a reduced overall weight of 15-20%,
have a decreased brain weight as well as minor defects in locomotion, gliosis and long-term
potentiation (Zheng et al., 1995; Magara et al., 1999). Since APP-KO mice are viable and fertile
AP, alone, cannot play a key role in development. However, studies utilizing double knockouts
of APP and APLP2 have shown a lethal phenotype, suggesting that there is redundancy in the
function of APP and APLP2 (Heber et al., 2000).
The structure of APP resembles that of cell-surface receptors (Kang et al., 1987) and
growth factors receptors (Rossjohn et al., 1999). There is a hydrophobic site within the E1
domain that could potential be a protein binding site (Rossjohn et al., 1999). Some data indicate
that when heparin is bound, APP dimerizes at that hydrophobic pocket (Gralle et al., 2006).
Previously noted, there are additional dimerization spots in the E2 domain of APP. Specifically
the E2 region is responsible for antiparallel dimerization (Wang & Ha, 2004). APP can
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homodimerize or heterodimerize with APLP1 and APLP2 (Khalifa et al., 2010). Dimerization of
APP within the ectodomain can aid in cell to cell adhesion and interaction, but dimerization
closer to, or within the membrane seems to regulate APP processing. Although a clearly defined
function of APP is not available, it is reasonable to conclude that APP plays a role in growth,
regulation, and cell-cell interactions to some extent.
APP mRNA is translated by membrane bound polysomes, and immediately following,
the N-terminal peptide signal is removed. The mature APP peptide translocates to the ER where
it continues to the Golgi apparatus and trans Golgi network (TGN). Throughout these sites, many
posttranslational modifications occur, such as glycosylation, phosphorylation, palmitoylation,
ubiquitination and sumoylation (Selkoe, 2001). All of these modifications lead to changes in
trafficking of APP, and therefore, secretase co-localization, which can affect Aβ production.
From the Golgi and TGN, around 10% of APP reaches the plasma membrane, but most remains
in the late stages of the secretory pathway (Choy et al., 2012). There also seems to be a small
fraction of APP that goes directly into endosomes from the TGN (Choy et al., 2012). At the cell
surface, APP is either rapidly cleaved by -secretases, or is internalized, due to the a C-terminal
endocytic signal within the AICD, via Catherin-mediated endocytosis (Yamazaki et al., 1996).
Once internalized, most APP enters the endosomal-lysosomal pathway, but a small fraction of
APP either gets recycled back to the cell surface or goes back to the TGN (Haas et al., 1992).
APP Regulation. As APP travels through the secretory pathway, it goes through many
posttranslational modifications, many of which effect trafficking of APP, and therefore APP
processing (Table 1).
First, as newly translated APP enters the endoplasmic reticulum (ER) it is glycosylated
on two residues (Asn467 and Asn496) by oligosacharyl transferase (OST) (Pahlsson et al.,
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1992). Once APP passes through to the Golgi apparatus, O-glycosylation occurs on many serine
or threonine residues. Both N-glycosylation and O-glycosylation are required for APP trafficking
to the plasma membrane (Greenfield et al., 1999). Interestingly, a special type of Oglycosylation, O-GlcNacylation, which consists of adding a -N-acetylglucosamine (GlcNAc) to
serine or threonine residues (Griffith et al., 1995), results in inhibition endocytosis of APP from

Table 1. APP modifications and the effects on localization and Aβ production
Modification:

Causes Localization
to:

Cleavage Increased:

Amyloid Beta
Production:

N-Glycosylation

PM

α-secretase

↓

O-Glycosylation

PM

α-secretase

↓

Ser655

TGN

α-secretase

↓

Thr668

N/A

β-secretase

↑

Lys651

PM

α-secretase

↓

Lys688

Golgi

α-secretase

↓

Lipid Rafts

β-secretase

↑

Phosphorylation

Ubiquitination

Palmitoylation

the membrane (Chun et al., 2015). Since -secretase is found in the secretory pathway
and at the plasma membrane, glycosylation of APP leads to decreased A by colocalizing APP
with -secretase.
APP is can also be phosphorylated at ten sites; eight are located in the cytoplasmic
domain, and the other two are found in the ectodomain (Gandy et al., 1988). The more influential
phosphorylation sites occur in the cytoplasmic domain, and the most notable of the 8 are Ser655
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and Thr668. Ser655 can be phosphorylated by protein kinase c (PKC), Ca++/Calmodulindependent protein kinase II, or APP kinase I (Gandy et al., 1988; Isohara et al., 1999; Suzuki et
al., 1992). The majority of phosphorylated Ser655 is found in mature APP, while
phosphorylated Thr668 is found in immature APP, as this modification normally takes place in
the ER (Oishi et al., 1997; Muresan & Muresan, 2012). Thr668 can be phosphorylated by
glycogen synthase kinase 3 (GSK3), cyclin dependent kinase 5 (CDK5), CDK1, stressactivated protein kinase 1 (SAPK1), c-jun N-terminal protein kinase (JNK) (reviewed in
Wang et al., 2017). Ser655 phosphorylation leads to increased APP trafficking to the TGN, and
reduced trafficking to the lysosomes. This leads to decreased A production by localizing more
APP within the secretory pathway, therefore placing APP in an ideal location for -secretase
cleavage. However, with Thr668 phosphorylation, there is no effect on APP trafficking but an
increase in A production is seen do to modified protein interactions. Thr668 causes a
conformational change which blocks the binding of Fe65 at the YENPTY motif (Ando et al.,
2001). Fe65 is an adaptor protein that is known to cause translocation of APP to the plasma
membrane when bound (Sabo et al., 1999). By blocking the binding of Fe65 through Thr668
phosphorylation, A secretion is increased. One of the other notable sites for APP
phosphorylation is Tyr687, which causes APP trafficking to the secretory pathway, increasing secretase cleavage and therefore A production (Zambrano et al., 2001).
APP is also ubiquitinated within its cytoplasmic domain. Ubiquitination signals for
degradation, translocation, and aids in protein-protein interactions. There are two main sites for
this modification in APP, Lys651 and Lys688. Lys651 ubiquitination, in neurons, leads to
increased APP trafficking to the plasma membrane, and increase -secretase cleavage
(Watanabe et al., 2012). Lys688 ubiquitylation aids in translocation of APP to the Golgi,
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therefore decreasing A production as well (Hiltunen et al., 2006). Overall, ubiquitination seems
to be nonamyloidogenic.
Palmitoylation can occur on two cysteine residues in APP, specifically Cys186 and
Cys187, but only around 10% of all APP undergoes this modification (Bhattacharyya et al.,
2013). Palmitoylation is the process of adding fatty acids to cysteine residues and occurs in the
ER. Once the palmitoylated APP reaches the plasma membrane, it is more likely to be sorted into
lipid rafts, due to the added fatty acid. BACE-1 is highly localized to lipid rafts within the
plasma membrane, so there is a higher probability for  cleavage of APP, increasing A
production following palmitoylation.
Regulation of APP processing also occurs through protein interactions at the YENPTY
motif within the cytoplasmic domain, and through dimerization. While the mechanism is not
clearly understood, X11 proteins play a role in regulation of APP processing. If X11 is
overexpressed, the half-life of APP is significantly increased, and the production of sAPP and
A is inhibited (Sastre et al., 1998). This indicates that binding of X11 to the YENPTY motif of
APP results in inhibition of both -secretase and BACE-1 cleavage.
Further linking APP to development, the disabled (Dab) gene family proteins interact
with APP at the YENPTY motif and increase the concentration of mature cellular APP, although
the mechanism by which this occurs is not well understood. These adaptor proteins regulate the
positioning of neurons throughout the brain during embryogenesis. By increasing the amount of
mature APP, there is more BACE-1 cleavage, due to the increased amount of substrate. Simply,
mDab1 interaction with APP increases A production. mDab1 can also bind to Fe65 to inhibit
Fe65 interaction with APP to further increase A production (Kwon et al., 2010).
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Another regulation through protein interaction occurs with neuronal sorting proteinrelated receptor (SorLA). Inside of endosomes, SorLa allows for interaction between APP and
retromer (Small et al., 2006). This signals for APP to go through retrograde transport to the
TGN, before being cleaved by BACE-1 inside of the endosome. Interestingly, brain-derived
neurotrophic factor (BDNF) upregulates SorLA expression via ERK signaling (Rohe et al.,
2009). Overall, SorLA and APP interaction downregulates A by initiating retrograde transport
inside the endosome (Lee et al., 2008).
Dimerization of APP, whether homo- or hetero-, allows for cellular adhesion and
communication, but also plays a major role in the regulation of APP processing. APP that is
dimerized within the cytoplasmic domain is naturally done two ways; it can be via the GxxxG
motif, or through GxxxA. GxxxG based APP dimers allow for BACE1 cleavage, and -secretase
cleavage (Kienlen-Campard et al., 2002). However, if a point mutation occurs, and the motif
switches to a GxxxA sequence, the  cleavage from -secretase is allowed, to release the amyloid
precursor protein intracellular domain (AICD), but the  cleavage site is blocked (KienlenCampard et al., 2008). This means that the generally positive effects of the AICD are still
allowed, but the production of A is inhibited.
Neuronal activation regulates APP processing (Figure 3). When an action potential
reaches the synaptic terminal of a neuron, there is an influx of calcium. This causes the fusion of
synaptic vesicles with the plasma membrane so that the contained neurotransmitter may be
released into the synaptic cleft. The fusion of synaptic vesicles leads to increased clatherinmediated endocytosis so that the fused synaptic vesicles can be removed from the cellular
membrane, however, with this upregulation of endocytosis, there is increased APP
internalization (Cirrito et al., 2008). APP internalization leads to increased APP inside of early
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and late endosomes where the majority of A production occurs (Lah & Levey, 2000). In
humans, brain areas with the most activity throughout life are the most prone to A accumulation

Brain Extracellular
Space

Figure 3. Pathway of neuronal activity modulation on APP endocytosis. (Adapted from
Cirrito et al 2008).

(Buckner et al., 2005). Interestingly, there are also many links between stress-induced
neuronal activity and AD (Wilson et al., 2005). Together, this indicates that neuronal activity
leads to an increase in A production by inducing colocalization of APP and BACE1. With this,
there is a clear mechanism linking neuronal activity with increased A production.
APP Processing. The majority of APP is processed by three families of enzymes; secretases, -secretases and -secretases. APP is either cleaved by an -secretase or -secretase,
but after cleavage by either of those enzymes, is always cleaved by -secretase (Figure 4).
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-secretase Cleavage. There are several zinc metalloproteinases that can function as secretases including, ADAM 9, ADAM 10, ADAM17 and ADAM19 (Allinson et al., 2003).
ADAM10 is the most common -secretase in neurons (Kuhn et al., 2010).

Figure 4. Summary of APP processing pathways
APP is either cleaved by α -secretase or BACE1 to enter the nonamyloidogenic or amyloidogenic, respectively.
The nonamyloidogenic cleavage results in sAPPα and C83 (CTFα ), whereas BACE1 cleavage results in sAPPβ
and C99 (CTFβ). In either pathway, γ-secretase subsequently cleaves the membrane tethered CTF. In the
nonamyloidogenic pathway, p3 is released. In the amyloidogenic pathway Aβ is secreted. In both pathways, the
APP intracellular domain is liberated. (Adapted from Querfurth and LaFerla 2010).

Most -secretase cleavage occurs at the plasma membrane (Sisodia, 1992), however,
there is also -secretase activity within the TGN where the majority of APP resides (Skovronsky
et al., 2000). There are many ligands that are cleaved by -secretases, including Notch,
cadherins, IL-6 and tumor necrosis factor , all of which are type I transmembrane proteins, like
APP. When -secretase cleavage occurs, the extracellular portion of the ligand is normally
secreted.
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Cleavage of APP by -secretase is the first step in the non-amyloidogenic processing of
APP. This processing of APP occurs between Lys16 and Leu17 within the E2 extracellular
domain (Esch et al., 1990). This cleavage takes place within the A sequence, therefore
preventing the liberation of the A peptide during subsequent cleavages. APP is cleaved by secretase at the plasma membrane or throughout the golgi apparatus and TGN. Cleavage the
plasma membrane prevents APP from being endocytosed and deliver to early and late
endosomes, where amyloidogenic cleavage would have likely occurred. Following -secretase
cleavage, secreted APP  (sAPP) and the C-terminal fragment  (CTF) are produced.
The sAPP has been shown to be neurotrophic and neuroprotective by many studies
(Hick et al., 2015; Plummer et al., 2016; Hefter & Braguhn, 2017). While the specific role of
sAPP, much like the role of APP is unclear, there have been many studies done that begin to
elucidate possible mechanisms of action. In healthy patients, the cerebral spinal fluid (CSF)
sAPP levels are significantly higher than patients with AD (Lannfelt et al., 1995). That added
with the fact that decreased sAPP is correlated with decreased spatial memory in humans
(Almkvist et al., 1997), is one of the primary arguments as to how sAPP is neurotrophic.
Some argue that all of the neuroprotective functions of APP, like cell growth, cellular
interactions and regulations, can be attributed solely to sAPP (Hornsten et al., 2007). Furthering
this, the deleterious effects in APP KO mice, like body and brain weight, decreased locomotion
ability, and impaired LTP are fully restored with expression of sAPP (Ring et al., 2007). While
APP/APLP2 KO mice are not viable, the introduction of sAPP rescues the lethal phenotype
(Weyer et al., 2011). sAPP has been seen to protect normal memory function and to increase
neuronal survival (Meziane et al., 1998; Roch et al., 1994).
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Extensive research has been done to evaluate sAPP as a potential therapeutic target, not
just for AD but for traumatic brain injuries as well. An induced expression of sAPP resulted in
decreased cell and axonal death and improved motor outcomes following traumatic injury in rats,
compared to rats left to recover without intervention (Thornton et al., 2006). However,
overexpression of sAPP promotes tumorigenesis due to its role in cell growth (Chasseigneaux
& Allinquant, 2012). For this reason, using sAPP upregulation as a possible therapeutic target
has many drawbacks (reviewed in Nhan et al., 2015).
Finally, there is evidence that the functions of sAPP, and therefore the functions of APP
come from the RERMS sequence, specifically the RER, within the E2 domain (Morrissey et al.,
2019), at least when it comes to LTP. With infusion of the RERMS penta-peptide into rat brains,
there is an increase in synaptic density as well (Roch et al., 1994).
Overall, the release of sAPP, following -secretase cleavage of APP, has neurotrophic
and neuroprotective effects.
CTF remains tethered to the membrane following -secretase cleavage. CTF is also
known as C83 due to the number of amino acids left in the peptide. There is little known about
any function CTF might have other than remaining in the membrane until -secretase cleavage
occurs to liberate the cytoplasmic domain of CTF.
-secretase Cleavage. -site amyloid precursor protein cleaving enzyme 1 (BACE1) is a
membrane bound aspartyl protease, indicating that it contains two aspartyl groups inside the
active site, which resides in the extracellular space (Hong et al., 2000). Aspartyl groups are very
acidic, which is what gives most membrane bound aspartyl proteases the ability to function at
low pH’s, between two and four. BACE-1 can be found in endosomes, the TGN, (Kinoshita et
al., 2003) and within lipid rafts throughout the plasma membrane (Ehehalt et al., 2003). BACE-1
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has optimal activity at low pH’s, similar to that found in early and late endosomes. Similar to
APP, BACE1 goes through many posttranslational modifications which effect its localization,
and activity. BACE1 is synthesized in the endoplasmic reticulum, and immaturely, is a 501amino-acid peptide (Capell et al., 2000). In the ER, BACE1 is glycosylated on four Asn residues
(Haniu et al., 2000), and seven Arg residues (Costantini et al., 2007). Following these
posttranslational modifications, BACE1 translocates to the Golgi apparatus where further
glycosylation occurs as well as the removal of its prodomain by furin convertases (Bennett et al.,
2000).
Mature BACE1 is trafficked to the plasma membrane. Phosphorylation on Ser498 of
BACE1 signals for internalization from the membrane into endosomes (Pastorino et al., 2002).
Palmitoylation of BACE1 also can occur on four Cys residues that are close to the
transmembrane domain. (Vetrivel et al., 2009). The addition of fatty acids to those cysteine
residues facilitate BACE1 translocation to lipid rafts within the plasma membrane.
BACE1 cleavage is the first step in the amyloidogenic processing pathway of APP.
BACE1 cleaves APP within the E2 domain, much like -secretase, but differs because its
cleavage site, between amino acids 671 and 672 produces the N-terminus of the A peptide
(Figure 4). The beginning of A is also the N-terminus of the CTF, which is slightly shorter
than the CTF. The cytoplasmic portion, sAPP, is shed following BACE1 action.
Not much is known about the function of sAPP; however, it is thought to hold many of
the same neuroprotective properties as sAPP, but it is 100x less powerful than sAPP, so its
effects are rarely seen (Furukawa et al., 1996). This proteolytic fragment does not regulate LTP
CTF remains tethered to the membrane following BACE1 cleavage. CTF is also
known as C99 due to the number of amino acids left in the peptide. There is little known about
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any specific unction CTF might have other than remaining in the membrane until -secretase
cleavage occurs to liberate the cytoplasmic domain of CTF as well as A.
-secretase Cleavage. The last proteolytic cleavage of APP is performed by -secretase,
another aspartyl protease (Figure 4). Rather than being a single protein, -secretase is a complex
containing four subunits with the catalytically active subunit being presenilin (PSEN) (reviewed
in Steiner et al., 2008). PSEN has two homologs, PSEN1 and PSEN2, and either can be the
catalytic subunit in unit in -secretase because they both contain two aspartyl groups inside of the
sixth or seventh TMD (Wolfe et al., 1999). Both homologs contain nine TMD (Spasic et al.,
2006), and to reach maturation, go through autocatalysis to become 2 subunits; the N-terminal
fragment and the C-terminal fragment. Three other subunits are require for PSEN stability and
optimal activity. Nicastrin (NCT), a type I integral membrane protein, is the second part of the secretase complex (Yu et al., 2000), and may play a role in selecting substrates based on size
(Shah et al., 2005; Dries et al., 2009). However, the role of NCT within the complex is still
heavily debated. Anterior pharynx-defective phenotype (Aph-1) is another subunit in -secretase
(Goutte et al., 2002), and while the exact function has not been elucidated there is speculation
that Aph-1 might be a scaffold protein, required for interaction of NCT and PSEN1 or PSEN2
(LaVoie et al., 2003). The presenilin enhancer protein (Pen-2) completes the -secretase
complex, contains two TMD (Francis et al., 2002), is thought to stabilize presenilin (Prokop et
al., 2004).
While identifying the specific structure of the -secretase complex has proven difficult, it
has been demonstrated that NCT and Aph-1 bind together inside of the endoplasmic reticulum
(LaVoie et al., 2003). Pen-2 binds to either of the presenilin’s, and then combine with the
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NCT/Aph-1 complex (Fraering et al., 2004). These four subunits have been identified to be
necessary and sufficient for -secretase cleavage.
Following initial cleavage of APP by -secretase or BACE1, a CTF is left behind
tethered to the plasma membrane, which is the substrate for -secretase. APP is processed by secretase is a step-wise fashion within the TMD (Figure 4 and 5). There are three cleavages that
are each performed around three amino acids apart (as reviewed in Haass et al., 2012). The first
cleavage is after either amino acid residues 48 or 49 and is called -cleavage.

Figure 5. Sequential Cleavages of APP by γ-secretase
ε-cleavage occurs first, and is typically after either amino acid 48 or 49. x-cleavage is second, and
happens following residues 46 or 45. γ-cleavage is last, and is variable, happening after residues
37, 38, 39, 40, 42, or 43. Here, the two main Aβ isoform production pathways are depicted.
(Adapted from Haass et al 2012.)

Subsequently, -cleavage takes place after residues 46 or 45. The last cleavage, called cleavage, is the most variable. This cleavage can take place after amino acids 37-43, but
normally takes place following residues 40 or 42 resulting in fragments named for their length,
i.e. A40 or A42.
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The fragments liberated by -secretase cleavage depend on the prior processing of APP.
If -secretase was responsible for initiating APP processing, then -secretase cleavage results in
a p3 peptide (Haass et al., 1993b), which is secreted extracellularly, and seems to be of little
pathologically importance. If BACE1 was responsible for beginning APP processing, then secretase cleavage liberates the neurotoxic A peptide (Seubert et al., 1992). -secretase also
produces AICD following -cleavage of APP, regardless of prior cleavages (Gu et al., 2001).
Although the AICD is produced in both pathways of APP processing, there is evidence
that the fragment is only transcriptionally active when rendered from the amyloidogenic pathway
(Nalivaeva & Turner et al., 2013). Since the AICD is a short and unstable peptide, confirming its
effects has been difficult. Within the AICD, the YENPTY motif and its possible interaction with
Fe65 aids to keep the peptide stable for translocation to the nucleus. Inside of the nucleus, the
AICD is thought to act as a transcriptional activator of many genes including, GSK3, and NEP
(Kim et al., 2003; Grimm et al., 2015). Increased levels of GSK3 protein could lead to an
increased amount of APP phosphorylated at Thr668, which as aforementioned, leads to an
upregulation in A production by increasing BACE1.
A Overview. AD is a very complex disease, and there are many mechanism’s
responsible for the pathology. The most widely accepted hypothesis used to describe AD is the
amyloid cascade hypothesis. The amyloid cascade hypothesis suggests that AD occurs due to an
imbalance between A production and clearance.
The A peptide is the hallmark of AD. There are many isoforms of A, which are
dependent on the -cleavage of -secretase. The most neurotoxic isoforms are A40 and A42
(Chen et al., 2017). After secretion, A peptides can aggregate together to form oligomers,
which recently, have been noted to be the most pathological (Selkoe & Hardy, 2016). A
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oligomers can aggregate to create fibrils, which can further aggregate to become senile plaques.
A treated hippocampal neurons have LTP inhibition and reduced synaptic spine density
(Shankar et al., 2008). Interestingly, A secretion following upregulated neuron activity negative
feedbacks to depress synaptic activity (Kamenetz et al., 2003). Levels of soluble A early in life
correlate to the levels of toxic multimers seen with aging (Fisher et al., 2016).
A Clearance. Decreased clearance of A is also noted as a possible reason for amyloid
deposition and plaque formation. A is cleared from the brain both enzymatically, and nonenzymatically. Enzymes involved in proteolytic degradation of A include neprilysin (NEP)
(Iwata et al., 2001), insulin-degrading enzyme IDE (Hersh, 2006), and metalloproteases
(MMPs), specifically MMP2, MMP9 and MMP14 (Yan et al., 2006; Liao & Van Nostrand,
2010).
NEP is a zinc-metalloprotease that regulates A levels through proteolytic cleavage. Both
A40 and A42 levels were 2-fold higher in NEP knockout mice compared to wild type controls
(Iwata et al., 2001) indicating NEPs role as an A mediator. NEP degradation of A likely
occurs in presynaptic terminals because of its classification as a type II membrane-associated
peptidase (Turner et al., 2001; Iwata et al., 2004). There is evidence to suggest that NEP
accounts for 50% of total A clearance (Saito et al., 2003). While NEP is known to clear
monomeric A, whether it clears toxic oligomers is controversial. There is evidence
demonstrating NEP clearing A oligomers (Huang et al., 2006; Kanemitsu et al., 2003), but there
are also contradictory findings (Meilandt et al., 2009; Lessring et al., 2003).
IDE is also a zinc-metalloprotease, but unlike NEP is known to only degrade monomeric
A due to its unique structure (Shen et al., 2006). IDE resembles a clam shell, with the internal
pocket being the active site for A degradation. Due to the small nature of the opening to the
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internal pocket of IDE, oligomers cannot fit and therefore, are not degraded by IDE. IDE is
known to be localized in the cytosol (Falkevall et al., 2006) and the mitochondria (Leissring et
al., 2004), but other cellular locations are less certain including endosomes, the endoplasmic
reticulum and lysosomes.
While MMP2, 9 and 14 have been implicated in A clearance, compared to NEP and
IDE, MMPs are very weak modulators of A levels. Deletion of either MMP2 or MMP9 resulted
in small, but significantly different, changes in A throughout the cortex and hippocampus (Yin
et al., 2006). However, it seems that with increases in A deposition, production of MMPs is
upregulated (Yin et al., 2006).
Non-enzymatic pathways include bulk flow into the CSF by ISF draining through the
perivascular basement membranes (Bedussi et al., 2015), and transfer across the blood-brain
barrier (BBB) by LRP1 (Storck et al., 2015). While A can freely flow through the glial barrier
of the BBB, the endothelial tight junctions prevent free transfer of A into the peripheral
circulation (Storck et al., 2015). In order to transport A through these tight junctions specialized
transporters like low-density lipoprotein receptor-related protein 1 (LRP1). Various studies
suggest that LRP1 is the main transporter of A across the BBB (Ito et al., 2006). LRP1
transports A40 much fasters than A42 (Storck et al., 2015; Deane et al., 2008).

Factors Affecting AD Pathology
Physical Activity. There are many different types of exercise, ranging from aerobic
exercise, like running, to strength training, like lifting weights. There are also forms of
multicomponent training that involved aerobic, muscle strength and coordination exercises. All
forms of exercise provide important health benefits such as increases in cardiac output, which
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leads to increased blood flow. In the brain, raised blow flow can provoke numerous neurotrophic
mechanisms, like angiogenesis, synaptogenesis and neurotransmitter uptake (Zigmond et al.
2012; Radak et al. 2014). Exercise seems to be neuroprotective against neurodegenerative
diseases, such as AD, by attenuating their progression (reviewed in Sutoo & Akiyama 2003;
Leem et al 2011; Zigmond et al 2012). In addition to the different types of exercise, there are
divisions of physical activity that define whether an activity is exercise.
Divisions of Physical Activity. Physical activity involves any voluntary movement of the
body, that expends energy. Physical activity includes, but is not limited to, running a marathon,
biking, swimming, and even gardening. There is acute physical activity and chronic physical
activity (Figure 6). Chronic physical activity refers to repetitive bouts of physical activity,
whereas acute physical activity refers to a single session. Acute physical activity can be divided
into normal daily physical activity and exercise. Normal daily physical activity includes things
like gardening, walking to a class, and cooking dinner. Exercise is more structured than normal
daily physical activity and includes swimming, playing in a pick-up basketball game or going for

Figure 6. Divisions of physical activity. (Adapted from Yuede et al., 2018).

Figure ???. Divisions of Physical Activity

a walk after dinner. Chronic activity is typically structured and is a regimen that repeats with a
long-term goal of improving overall health.
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Chronic physical activity can be split into exercise training and sub-exercise training.
Exercise training (ET) is chronic physical activity, where a measurable training effect
occurs. The training effect could be a variety of things including increased muscle strength, or
increased levels of a Krebs cycle enzyme. Citrate synthase is a commonly used to confirm
exercise training (Moore et al., 2016; Thomas et al., 2020). Once the exercise bouts are no longer
creating a measurable training effect, it becomes sub-exercise training. For example, if someone
ran 2 miles a day for 4 weeks, and each time they ran it, they were improving their times, and it
was easier, that is exercise training, but once running 2 miles becomes easy and is not improving
general fitness, it is sub-exercise training.
Exercise Training and AD. There are many health benefits of ET including a decreased
risk for AD development (Laurin et al., 2001; Wilson et al., 2002). Many exercise studies are
performed using transgenic mouse lines. There are two forms of exercise administered in the
literature, forced and voluntary. Forced increases the psychological stress associated with the
exercise, but additional variables such as exercise intensity or length can be controlled. Forced
running is administered by placing mice on treadmills, while voluntary running typically takes
place on a wheel. Forced running decreased A compared to sedentary animals (Yuede et al.,
2018), suggesting that if the intensity of the exercise is high enough, the negative effects of
psychological stress from being forced to run, are overcome by the benefits of ET. There seems
to be an intensity “threshold” where exercise above the threshold show beneficial effects, but
exercise below shows no neuroprotective effects (Yuede et al., 2018). The beneficial properties
of exercise in relation to AD, such as decreased A and increases in the proteins responsible for
A clearance are increased in a dose-dependent manner (Moore et al., 2016; Thomas et al.,
2020). Therefore, high intensity exercise is more beneficial than moderate intensity exercise in
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the attenuation of AD progression. In a transgenic mouse model, such as APP/PS1, an exercise
regimen of 15 m/min, 60 min/day, 5 days a week that lasts for 8 weeks is above the intensity
threshold and will elicit an exercise training effect (Yuede et al., 2018).
Exercise training causes an increase in brain-derived neurotrophic factor (BDNF) (Huang
et al., 2014; Ferris et al., 2007). BDNF is a marker for general brain health due to its
neuroprotective properties (Acheson et al., 1995). High levels of BDNF expression are seen in
the hippocampus and cortex, as well as other areas crucial for memory development. BDNF
contributes to synaptic growth and plasticity and modulates long-term potentiation in the
hippocampus (Lu et al., 2014). In people with AD, lower levels of BDNF are observed (reviewed
in Ng et al., 2019). Increased levels of BDNF due to exercise could be one of many ways ET
leads to cognitive benefits as seem in many humans afflicted with AD, as well as mouse models
(Chapman et al., 2013; Yu et al., 2006; Thomas et al., 2020).
Stress. Stress can be anything that causes a temporary upset in homeostasis. Stress can be
categorized as physical or psychological. In general, stress can be regarded as a mental or
physiological challenge. Physical stress could include having an illness, going for a walk, or
being outside in the cold. Psychological stress is emotional or cognitive stress. Examples include
feeling guilty after an argument with a friend, losing a loved one, or being worried about an
upcoming exam. While acute stress in generally harmless, prolonged stress increases the risk for
development of AD, and can exacerbate symptoms (Dong & Csernansky, 2009; Wilson et al.,
2003, 2006; Machado et al., 2014).
Molecular Pathway of Stress. When a stressor is detected the hypothalamic-pituitaryadrenal (HPA) axis and sympathetic nervous system are activated. The periventricular nucleus is
in the hypothalamus and responds to neuronal impulses indicating stress by activating
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specialized neurons to secrete corticotropin-releasing factor (CRF). CRF travels to the anterior
pituitary gland and stimulates the production and secretion of adrenocorticotropic hormone
(ACTH). Once ACTH reaches the adrenal cortex, it signals for the production and secretion of
glucocorticoids (GC), including cortisol (Ulrich-Lai & Herman, 2009). Generally, cortisol is
responsible for increasing blood glucose levels during a stressful event and modifying fat and
protein metabolism (Stephens & Wand, 2012). However, when in high concentrations, cortisol
can also influence learning and memory and cardiovascular function (Adinoff et al., 2010).
While the neuroendocrine response to all stressors is largely the same, physical stress is typically
accompanied by an upregulation in growth hormone levels, unlike psychological stress (Ranabir
& Reetu, 2011).
Stress and AD. While the mechanism whereby stress increases the progression of AD is
not completely known, there are several studies that demonstrate that chronic stress affects AD
through increased GC signaling following prolonged HPA axis activation (Salvagioni et al.,
2017; Rehman, 2002). Cortisol levels correlate with the severity of cognitive decline seen in AD
(Pedersen et al., 2001), illustrating that amplified GC levels may have a role in overall cognition
deficits seen in those with AD. In transgenic AD mouse models, mice treated with a
corticosteroid had increased APP, A, and BACE levels (Green et al., 2006). This demonstrates
a direct link between increased GC levels are AD progression through A production. Recently,
one study revealed a link between GC-related pCREB transcriptional activation and increased
BACE1 (Choi et al., 2017). These studies have depicted a relationship between stress signaling
and increased A production, leading to exacerbation of AD symptoms, therefore decreasing
cognition. There is also evidence that increased CRF signaling through the CRF receptor 1
(CRFR1) is present in AD patients (Behan et al., 1995), and can increase AD pathogenesis
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(Campbell et al., 2015). CRFR1 signaling influences A production by modulating -, -, and 
secretases (Park et al., 2015; Thathiah & Destrooper, 2011). Interestingly, temporary activation
of CRFR1 pathways decreases A production by shifting APP processing towards the secretase-mediated pathway; however, with chronic activation of
CRFR1, APP processing shifts towards the -secretase-mediated pathway, resulting in toxic A
peptides (Willem et al., 2015).
Stress and Exercise. Although exercise is a considered a physiological stressor, chronic
exercise may be protective against stress (Tsatsoulis & Fountoulakis, 2006). Chronic
psychological stress and chronic exercise stress differ at a molecular level. When evaluating the
effects of both types of chronic stressors, those who participated in the chronic exercise regimen
had the same levels of cortisol as sedentary “non-stressed” individuals when awakening (Labsy
et al., 2013). However, subjects who underwent chronic psychological stress had increased
cortisol levels upon awakening compared to controls (Wüst et al., 2000). Interestingly, the
conversion of cortisol to cortisone increases directly with the amount of exercise completed but
does not increase proportionally to chronic psychological stress (Gourané et al., 2005).
Therefore, the difference in chronic psychological or physical stress may be related to the
conversion of cortisol into cortisone.
Another way in which physical and psychological stress differ is through the modulation
of an endocannabinoid, anandamide (AEA), which easily crosses the blood-brain barrier and
seems to play a role in improving mood following exercise. AEA increases following exercise
(Heyman et al., 2012) but decreases following psychological stress (Gunduz-Cinar et al., 2013).
Interestingly, psychological stress increases fatty acid amide hydrolase, which breaks down AEA
(Reich et al., 2009). As mentioned earlier, exercise leads to an increase in plasma BDNF,
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however, there is evidence to suggest that AEA is required for BNDF levels to remain elevated
after exercise (Heyman et al., 2012), and it may serve as a mediator of the BNDF effect on longterm potentiation and memory. As an endocannabinoid, AEA binds to cannabinoid receptor type
1 (CB1R) and exercise leads to an increase in the density of CB1R in the hippocampus in rats; a
region of high importance for memory formation (Hill et al., 2010). If CB1Rs are blocked,
exercise-induced BDNF increase is diminished (Ferreira-Vieira et al., 2014), illustrating a
relationship between BDNF levels and AEA binding. The exact mechanism of this relationship is
unknown.
Voluntary exercise is generally more beneficial than forced exercise of the same intensity
because it is perceived as less of a psychological stressor (Yuede et al., 2009 & Yuede et al.,
2018). However, at higher intensities forced exercise still slows the progression of AD pathology
(Yuede et al., 2018). Chronic exercise can train the body to be more resilient to both
psychological and physical stressors, which can prevent exacerbation of AD (Cavalcante et al.,
2017).
Serotonin. Serotonin has been linked to many behaviors and processes, including food
intake, motor function, neuron firing rate, sexual arousal, reproduction abilities, mood and fetus
maturation. Recently, serotonin has been shown to decrease the production of amyloid beta,
when SSRI’s are used, further linking A.D. and depression.
Serotonin (5-HT) is a tryptophan derivative, that is produced following two subsequent
enzymatic modifications by tryptophan hydroxylase and l-amino acid decarboxylase (Azmitia,
2010). Tryptophan is an essential amino acid and therefore is acquired by dietary intake only;
however, it is not found in high quantities in the body due to the competition for transport into
the brain with other, more abundant amino acids, and due to the average diet (Azmitia, 2010).
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Tryptophan is more concentrated in fruits, vegetables and nuts, rather than meat, because
photosynthesis is coupled to tryptophan production (Azmitia, 2010). As a consequence of the
minuscule tryptophan availability, serotonin synthesis is limited to mast cells and neurons, and is
produced in small quantities as well (Azmitia, 2010).
Despite the limited abundance of serotonin, it still plays a major role in many human
processes. This can be attributed to the diversity of receptors (5-HTR) and the presence of
binding proteins that aid to transport of 5-HT to specific regions. There are 7 main 5-HTR
families (5HT1R- 5HT7R) (Bockaert et al., 2010).
Serotonin and AD. Serotonin concentrations effect the progression of AD. When
selective serotonin reuptake inhibitors (SSRIs) are used, in mice and humans, a reduction in A
levels is seen in both the hippocampus and the cortex (Fisher et al., 2016). Upon binding of
serotonin to certain receptors, specifically G protein-coupled receptors that activate cyclic AMP
dependent kinase (PKA), lead to Raf activation. Then, Raf activates MEK, which phosphorylates
ERK. Phosphorylated ERK can either remain in the cytoplasm where it acts to phosphorylate
proteins, or it is transported to the nucleus to act as a transcription factor. In the case of A level
reduction, it appears that ERK phosphorylates -secretase, increasing its activity (Fisher et al.,
2016). However, there were no reductions in BACE-1 activity. This indicates that the increased
activity of -secretase limits the amount of available ligand for -secretase to cleave. The
stimulation of serotonin receptors effects the production of A rather than the clearance.
Serotonin receptor subtypes 4, 6, and 7 regulate A concentrations (Fisher et al., 2016).
Interestingly, even though inhibiting any one receptor does not alter A levels, stimulation of
one is enough to reduce A levels by the same amount as when all of them are stimulated. This
suggests redundancy in this mechanism.
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Serotonin and Exercise. Exercise may elevate serotonin levels by increasing the
likelihood that tryptophan crosses the BBB (Patrick & Ames, 2015). Since exercise requires
muscle activity, and active muscles require branched-chain amino acids, this limits the
competition of BBB transport for tryptophan. Exercise increases serotonin in the cortex
(Meeusen & De Meirleir, 1995), but decreases 5HT levels throughout the hippocampus
immediately following exercise (Dey et al., 1992).
There are clear links between AD and exercise training, as well as AD and stress, and AD
and serotonin however, to date, there have been no studies examining the effects of the
interaction of exercise training and isolation stress on the serotonergic system in an AD model.
This study aims to identify the effect of an exercise training regimen and isolation stress on
serotonin levels in the cortex and the hippocampus, as well as serotonin receptors 4, 6 and 7.
Other aims of this study is to investigate a possible correlation in serotonin and A levels
following treatment, in addition to exploring a relationship of BDNF and CRF levels with
serotonin levels.
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MATERIALS AND METHODS

Experimental Design
Forty-eight APP/PS1 mice with the appswe/ps1de9 trans genes and a C57BL/6J genetic
background were divided into 8 different groups in this study. All procedures involving the live
mice were approved by Missouri State IACUC under protocol 2019-1 (Appendix). Four female
and four male groups were further separated by the type of housing they were subjected to, as well
as by the exercise treatment they received (Figure 7).

GROUP
NAMES
6 Females

SEF

6 Males

SEM

6 Females

SSF

6 Males

SSM

6 Females

IEF

6 Males

IEM

6 Females

ISF

6 Males

ISM

12 ET
24 SOCIAL
12 SED
48 APP/PS1
Mice
12 ET
24
ISOLATED
12 SED

Figure 2. Treatment Group Summary
Figure 7. Experimental design for animal groups.
Mice were split into 8 treatment groups based on sex, exercise treatment and housing type.

Animal Treatment. All mice were obtained through an in-house breeding colony. In
order to determine which pups had the APP/PS1 genes, genotyping was preformed between 12
and 21 days of age (Figure 8).
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Genotyping. Briefly, tail samples were taken from each mouse, a number assigned, and
the tail marked for identification. QIAamp DNA Mini Kit from QIAGEN was used to extract
DNA, and the samples were then analyzed by PCR using 3 primers from IDT based off of the
Tg(APPswe,PSEN1dE9)85Dbo-Chr9 genotyping protocol from JAX laboratories, as well as
GoTaq Green Master Mix from Promega. One of the primers is found in both the wild type and
the transgenic mice, acting as the reverse primer, while each of the other two primers are specific
to either the APP/PS1 or wildtype genotype. In hemizygous mice, which was the genotype
utilized, both of the genotype specific primers work. PCR products were run on a 2% agarose gel
using 1X TAE. For sample visualization, ethidium bromide was used. A 100-bp ladder was ran
as a scale to predict the band sizes. The expected band sizes were142 bp for a transgenic mouse,

Figure 8. Experimental timeline.

and 265 bp for a wild type. Hemizygous mice had both bands. Mice used in studies were
tattooed for identification.
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Animal Housing. Routine care of the animals was handled by the animal husbandry staff
at Missouri State University. Mice were kept on a 12-hour light/dark cycle, and receive food and
water ad libitum. All mice will be socially housed until three months of age (Figure 3). The
socially housed animals were kept in ventilated cages with three to four mice per cage. At three
months, the mice in the IEF, IEM, ISF, or ISM group were moved to isolated housing (Figure 3).
These animals lived alone in the same cages, but a divider reduced the cage to about a third of its
normal area. Cages for isolated housing were placed so that the mice could not see other mice.
Exercise Training Regimen. Exercise training (ET) began concurrently with housing
relocation (Figure 3). All ET sessions occurred during the dark cycle and took place in a
darkened room. All mice were placed on a 6-lane treadmill equipped with a mild electric current
at the end of the lane for encouragement. Gentle mechanical encouragement was also provided
by the researchers, who were present for all ET sessions to records levels encouragement needed
for each animal. Mice were kept on the same lane for the duration of the training. The first week
of ET was an acclimation period, where the mice ran at increasing speeds until they reached 20
meters per minute. After the acclimation week, the ET mice ran at 20 meters per minute for 60
minutes Monday through Friday for 10 weeks. The sedentary mice were placed on the treadmill,
with the same conditions as the exercised mice, but did not run.

Tissue Collection and Preparation
Dissections. The mice were dissected on the Monday following completion of the 10week exercise training regimen.
Preparations and Anesthesia. First, each mouse was weighed and the mass was recorded.
Simultaneously, the isoflurane vaporizer was prepped for use. Each mouse was placed into the
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anesthesia chamber. When breathing became slowed and the mouse became lethargic, the mouse
was placed onto dissection tray where a tube continuously supplied the mouse with isoflurane as
anesthesia. After checking to ensure the mouse is void of reflexes, the feet were pinned down.
Profusion. An incision was made at the xyphoid process, and the cut continued
superiorly. The ribs were cut through and the region was blunt dissected, exposing the heart. The
right atrium was cut while a saline syringe punctured through the left ventricle. The heart was
profused with a minimum of three 2.5 ml syringes of saline and continued until the heart stopped
bleeding. Once completed, the heart was removed to ensure lifelessness of the animal.
Brain Extraction. Dissecting forceps were clasped onto the skull, an incision was made at
the base of the head, and the region was blunt dissected. While ensuring the scissors were always
pointed up, so that the brain was not punctured, a cut was made, through the skull, towards the
frontal bone. To expose the brain, the sides of the forceps were used to ply back the skull on
either side of the cut. The brain was then carefully removed from the skull and placed onto a
petri dish on top ice. The carcass was moved to the solei extraction station.
Brain Dissection. First, the brain was separated into hemispheres. The medial brain
surface was placed facing upwards, with the cerebellum facing to the left. The brainstem was
teased out by rolling it into the rest of the brain and then down, exposing the hippocampus.
Using the pointed side of a metal spatula, the hippocampus was lifted out revealing white matter.
The cusp of the cortex that was over the hippocampus was then sliced off, and the white matter
was removed to the greatest extent possible. This is repeated for both hemispheres. The
hippocampi and cortices were weighed and flash frozen in liquid nitrogen before being stored at
-80C. Dissections of WashU mice separated the brain into multiple regions to store for potential
future projects. However, this is the method used for all mice relevant to this project.
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Solei Extraction. The carcass was placed in prone position and the skin of the inferior
hind leg was removed. One side of the forceps was slid between the tibia and the lower hind leg
muscles, and then the calcaneal tendon was cut. The muscles were then flipped back to reveal the
underside. The bright red thin muscle was located and identified as the soleus. One side of the
forceps was slid under the soleus to separate it from the mass of muscles, and the superior tendon
was cut. The soleus was removed and weighed before being flash frozen and then stored at 80C. This was repeated for both hind legs.
Tissue Preparation. For sequential extraction of proteins from brain tissues to be used in
ELISAs three buffers were used: PBS, Triton, and Guanidine. To make the PBS buffer, 9.9 ml
of 1x PBS was combined 100 ul of a protease inhibitor, made using apotinin and leupeptin. The
triton buffer was made by combining 100 ul of Triton X-100, 9.9 ml of PBS and 100 ul of a
protease inhibitor which was previously made at Washington University. The guanidine buffer
was made by mixing 9.9 ml of 5M Guanidine-Tris buffer and 100 ul of a protease inhibitor. All
buffers were placed on wet ice to chill prior to using.
Each sample tube first received 10 ul of the PBS buffer per 1 mg of tissue weight. The
tissues were then homogenized using a pestle by turning 12 turns to the right, 12 to the left and
then 12 right turns again. The pestle was cleaned with 70% ethanol and MiliQ water between
each sample. The samples were centrifuged for 25 minutes at max speed at 4C. The supernatant
was collected into another tube and kept on ice. This was repeated with triton instead of PBS,
using the pellet remaining following supernatant removal. After spinning again, the triton
fraction was collected into another tube and chilled on ice. Guanidine was added to the residual
tube, at the same volume as the other two buffers. Samples were sonicated for 18 pulses at 50%
amplitude. The sonicator tip was cleaned with MiliQ water and dried between each sample to
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prevent contamination. The tubes were spun at max speed for 25 minutes at 4C, and the
supernatant was collected.

Protein Analysis
Total Protein Assay. Samples were first diluted, using MiliQ water, to a concentration of
1:50. For each well a sample was plated on, 100 ul of diluted sample was needed. Separate
curves had to be made for each extraction buffer used to account for excess background due to
the buffer interactions. For each curve 2143.75 ul of MiliQ water was combined with 43.75 ul of
the given extraction buffer (PBS/Triton/Guanidine). Eight tubes were used to make each curve.
The first tube received 250 ul of the H20/buffer mixture. For the second tube, 62.5 ul of the
Bovine Serum Albumin (BSA) from the ThermoFischer Pierce Protein Assay BCA and 437.5 ul
of the H20/buffer mixture were combined and vortexed. The final concentrations of all of the
tubes were as followed: Tube 1- 0 g/ml, Tube 2- 2500 g/ml, Tube 3- 125 g/ml, Tube 4- 62.5
g/ml, Tube 5- 31.25 g/ml, Tube 6- 15.625 g/ml, Tube 7- 7.81 g/ml, and Tube 8- 3.9g/ml.
A 96-well plate was loaded with 100 ul per well of sample or curve in duplicates.
Simultaneously, the working reagent from the ThermoFischer Pierce Protein Assay BCA kit was
prepared: 50 parts of reagent A, 48 parts of reagent B, and 2 parts of reagent C were mixed (1
part = 40 ul). The plate was loaded with 100 ul per well of the working reagent and incubated at
37C while covered until a color developed. Plates were read using a plate reader at 562 nm. The
concentrations given were exported to Microsoft excel, where they were multiplied by 50 and
divided by 1000 to reach mg/ml and account for the prior dilutions.
ELISA Analysis of Amyloid Beta. Beginning on the first day, a 6 ml solution of
carbonate coating buffer and 20 ug/ml of the HJ2 antibody (for A40) or 10 ug/ml of the HJ7.4
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antibody (for A42) was prepared and mixed by inversion 4 to 5 times. Using a 96-well plate, 50
ul of the solution was placed into each well. The plate was sealed and labeled, and then left to
incubate overnight in the 4C refrigerator on the rotator.
The following day, 2% BSA-PBS was prepared; some was diluted to 1% and the rest was
stored for up to 3 days. The plate was removed from the rotator and washed using the automated
plate washer, after making sure the washer had been primed using 1xPBS-0.05% Tween 20.
Residual liquid remaining following plate washing was removed, and 190ul of 1% BSA-PBS
was placed into each well. Then the plate was incubated for an hour at 37C. While plate was
incubating, samples and curve were prepared. Sample buffer (SB) was made by combining 5 ml
of 3M Tris, 250 ul of 10% Azide, 12.5 ml of 2% BSA-PBS, 500 ul of 100x Protease Inhibitor,
and 31.75 ml of 1xPBS-0.05% Tween 20. Samples were diluted using SB to different
concentrations based on what buffer was used to extract the solute from the brain tissue: PBS:
1:10, Triton: 1:20, Guanidine: 1:5,000. The SB used to make standard curves was spiked with
the corresponding buffer at different concentration equivalent to the sample concentrations: PBS:
5.94 ml of SB and 600 ul of PBS, Triton: 5.7 ml of SB and 300 ul 1% of Triton-PBS buffer, and
Guanidine: 5.999 ml of SB and 1 ul of 5M Guanidine-Tris buffer.
The curve was set up using 10 tubes. The stock tubes of A were centrifuged briefly prior
to pipetting from so to ensure even distribution of the dissolved protein. In the first tube, a
solution 680 ul formic acid (FA) and 8 ul A were combined and vortexed to ensure even
distribution of A. In the second tube, 8 ul of the previous tube, 80 ul of 3M Tris, and 712 ul of
SB were combine and vortexed. For the third tube, 12 ul of the previous tube and 988 ul SB were
combined, and mixed by pipetting. For the remaining tubes, excluding the last tube, 300 ul of the
previous tube and 600 ul of SB were combined and mixed by pipetting. The last tube received
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600 ul of SB. The calculated standard concentrations were as follows: B: 0 pg/ml, S1: 1200
pg/ml, S2: 400 pg/ml, S3: 133.3 pg/ml, S4: 44.4 pg/ml, S5: 14.8 pg/ml, S6: 4.9 pg/ml, and S7:
1.6 pg/ml.
The plate was loaded with the samples and the curves in duplicate or triplicate. After the
60-minute incubation was complete the plate was washed again with 1xPBS-0.05% Tween 20,
but the residual 1xPBS-0.05% Tween 20 was left in the wells. Wells were vacuumed dry, and
immediately filled with 50 ul of each sample. Samples were mixed by pipetting prior to loading
wells. The loaded plate was sealed and labeled and place into the 4C refrigerator on the rotator
overnight.
For day three, some 2% BSA-PBS was diluted to 6 ml of 0.05% BSA-PBS-T20 using
1xPBS-0.05% Tween 20. This was combined with the HJ5.1 Biotin antibody at a concentration
of 1:250. The plate was removed from the refrigerator and washed with 1xPBS-0.05% Tween 20
using the plate washer. The residual fluid was removed, and then the plate was loaded with 50 ul
per well of the HJ5.1 antibody in the 0.05% BSA-PBS-T20 mixture. The plate was incubated at
37C for 90 minutes, while 6 ml of 0.5% BSA-PBS-T20 was made using the stored 2% BSAPBS and 1xPBS-0.05% Tween 20. The 0.5% BSA-PBS-T20 was combined with the strep-Poly
HRP40 antibody at a concentration of 1:500. Upon completion of the incubation, the plate was
washed with 1xPBS-0.05% Tween 20 and the residual liquid was removed. The plate was loaded
with 50 ul per well of the strep-Poly HRP40 mixture, and then covered and placed on the shaker
at room temperature for 90 minutes. Afterwards, the plate was washed with 1xPBS-0.05%
Tween 20 and the leftover liquid was removed. The plate was loaded with 50 ul per well of
sigma superslow 3,3′,5,5′-Tetramethylbenzidine Liquid Substrate (TMB).
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Following TMB addition, plates were read at 2, 6 and 10 minutes using a plate reader.
The raw concentrations were exported to Microsoft excel where they were multiplied by 50 and
then divided by 1000 to get the concentration prior to dilutions. In order to normalize data,
substrate concentrations were divided by total protein concentrations. Concentrations reported
here are normalized proteins and expressed as picograms of amyloid per mg/ml of total protein.
Averages were found as well as standard deviations where applicable.
Citrate Synthase Analysis. Citrate synthase activity was tested using a kit and protocol
from Sigma Aldrich (cat No. Cs0720). Both solei muscles from each mouse were weighed,
placed together and 2 ml of CelLytic MT Cell Lysis Reagent (Sigma Aldrich No. C3228) was
added for each gram of tissue. Samples were homogenized and centrifuged at 20,000 x g for 10
minutes. The supernatant was collected and stored at -4C.
A master mix was made containing 186 ul of 1x assay buffer, 2 ul 30 mM Acetyl CoA,
and 2 ul 5,5′-Dithiobis-(2-nitrobenzoic acid) (DNTB) for each sample. After aliquoting the
master mix into each well, 8 ul of sample was added. Samples were loaded in triplicate.
Absorbances were read at 412 nm on a BioTek Epoch plate reader for 1.5 minutes each time.
Following collection of baseline absorbances, 10 ul of oxaloacetate was added to each well. Final
absorbances were read.
To calculate enzyme activity, the change in baseline absorbance was subtracted from the
change in final absorbance. The calculated absorbance was multiplied by 0.2 ml, and 20 to
account for the reaction volume and the dilution factor respectively. Then, the value was divided
by 13.6, 0.552 cm, .002 ml to account for the extinction coefficient of the TNB (the visual
product produced from DNTB reaction), the pathlength of absorbance of the 96 well plate, and
the volume of the enzyme in the sample respectively. To obtain the citrate synthase activity per
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gram of tissue, the previously calculated value was divided by the weight of the solei muscles.
The triplicate groups were averaged together.
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RESULTS

Standard Curve Practice
Single Practice Curve. To start practicing ELISA techniques, a single curve was
produced and loaded 10 times. The plate layout is depicted in Figure 9.

The plate was loaded in duplicate; meaning that A1 was loaded, then A2, and then B1
and B2, all the way down through H2. Then, columns 3 and 4 were loaded and so on.
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Sample concentrations are shown in Table 2. Blanks were all zeroed out, and although
not shown, absorbance values were between .06 and .07. Standard 1, which contains the largest
concentration, had to be covered across all 5 duplicate pairs as it was over the top of the curve.
This allows for accurate concentrations of actual samples to be given. Between standard 2 and
standard 7 values typically decrease with the exception of standards 5 or 6 (Figure 10). Within
standards, there is some variance (Table 3). For duplicate pairs 3, 4, and 5, standard 7 is less than
zero, like the blank. When comparing the average of each standard to the calculated values of
that standard the standard deviation is fairly low with the exception of Standard 1 (Table 3).
Standard 1’s average concentration is quite a bit lower than the calculated value. For this curve,
there is more variation between samples within the same standard, than between the average and
the calculated concentration. The R2 value of the experimental concentrations was 0.7843
(Figure 10).

Triple Practice Curves I. To continue practicing ELISA techniques, three curves
were made and loaded in triplicate. This means that columns 1 through 3 were loaded together,
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then 4-6 and then 7-9.
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Figure 10: Comparison of Experimental and Calculated Amyloid Standard Concentrations for the Single
Aβ40 Standard Curve
Calculated concentrations of the standard curve were compared to the actual values. Calculated values
are shown in blue with a R2 of 1, while the experimental values are shown in orange with a R2 of .7843.
The calculated standard concentrations were as follows: B: 0 pg/ml, S1: 1200 pg/ml, S2: 400 pg/ml, S3:
133.3 pg/ml, S4: 44.4 pg/ml, S5: 14.8 pg/ml, S6: 4.9 pg/ml, and S7: 1.6 pg/ml.

The plate layout is depicted in Figure 11. Curve concentrations are shown in Table 4. No curves
had decreasing tends moving from standard 1 to 7 (Table 4-5 and Figure 12).
All of the standards for curve 2, except for standard 1, had a concentration at or below
the background, resulting in a “LOW” reading (Table 4-5). This was also the case for curve 1
standards 6 and 7, as well as curve 3 standards 5-7 (Table 4-5). Standard deviation within
standards increased compared to the last practice curves (Table 3 and 5). Overall, concentrations
throughout the plates are extremely low, increasing variance between the expected values and the
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experimental values (Table 5). R2 values were unobtainable due to the lack of an overall
decreasing trend within the curves (Figure 12).

Triple Practice Curves II. To continue practicing ELISA techniques, three more curves
were made and loaded in triplicate. The loading pattern of the plate is depicted in Figure 13. The
curve concentrations are shown in Table 6. The blank fell between <0.00 pg/ml and 9.301 pg/ml
across all points of each curve. Standard 1 across all three curves was masked as it was over the
top of the curve. Standard 2 was also above the curve in one point for curve 1 and 2 points for
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Table 4: Concentrations of Aβ40 Standard Practice Curves in Triplicate #1
Concentrations (pg/ml)
Sample ID

Curve 1 (*)

Curve 2 (#)

Curve 3 (^)

Blank

<0.00

<0.00

<0.00

<0.00

<0.00

<0.00

<0.00

<0.00

<0.00

Standard 1

274.91

276.35

252.10

11.62

<0.00

8.18

262.21

211.84

250.90

Standard 2

259.58

289.59

279.646

LOW

LOW

LOW

275.23

217.44

295.08

Standard 3

271.32

286.09

180.72

LOW

LOW

LOW

293.32

262.71

304.75

Standard 4

351.32

234.61

246.42

LOW

LOW

LOW

290.54

231.52

303.45

Standard 5

117.37

86.95

94.79

LOW

LOW

LOW

LOW

LOW

LOW

Standard 6

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

Standard 7

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

LOW

curve 2 (Table 6). The blank values were close to standards 6 and 7. Curve 1 decreased
moving from standard 2 to 7, with the exception of standard 7 (Table 7).
Curve 2 decreased moving down the curve (Table 7, and Figure 14). Curve 3 had
decreasing concentrations moving down the curve with the exception of standard 7 (Table 7).
Within the same standard, variance is slim in comparison to past curves (Table 3, 5, and 7). As is
variance between the experimental and calculated values. For the experimental curve values the
R2 value were 0.88, 0.97 and 0.89 respectively (Figure 14).

WT/APP Practice Mice
After practicing ELISA techniques using only curves, practice samples were assayed.
Practice cerebellum sections were provided by Dr. John Cirrito’s lab at Washington University.
Tissues were weighed, had proteins extracted from the brain, and then put through the ELISA
procedure. Sixteen cerebellum sections were provided and weighed. Masses shown in Table 8.
All masses were similar and fell within 19.0 g to 42.0 g. Weights did not play a role in amyloid
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Table 5: Analysis of Aβ40 Standard Practice Curves in Triplicate #1
Standard Deviation
within Samples

Average
Concentration
(pg/ml)

Standard Deviation
between Calculated and
Average Values

1

13.60

267.79

659.17437

2

15.29

276.27

87.49

3

57.05

246.04

79.70

4

64.25

277.45

164.76

5

15.79

99.70

60.03

6

N/A*

N/A*

N/A*

7

N/A*

N/A*

N/A*

1

2.43

9.90

841.52778

2

N/A*

N/A*

N/A*

3

N/A*

N/A*

N/A*

4

N/A*

N/A*

N/A*

5

N/A*

N/A*

N/A*

6

N/A*

N/A*

N/A*

7

N/A*

N/A*

N/A*

1

26.43

241.65

677.66

2

40.34

262.58

111.97

3

21.74

286.93

108.61

4

38.35

275.17

163.15

5

N/A*

N/A*

N/A*

6

N/A*

N/A*

N/A*

7

N/A*

N/A*

N/A*

Standard Number
Curve 1

Curve 2

Curve 3

*

No data for this standard was available.
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Figure 12: Comparison of Experimental and Calculated Amyloid Standard Concentrations of Aβ40 Standard
Practice Curves in Triplicate #1
Calculated concentrations of the standard curve were compared to the actual values. Calculated values are
shown in blue with a R2 of 1, while the experimental values are shown in orange for curve 1, grey for curve
2 and yellow for curve 3. R2 were unable to be calculated as the values were too far off to generate a
exponential equation. The calculated standard concentrations were as follows: B: 0 pg/ml, S1: 1200 pg/ml,
S2: 400 pg/ml, S3: 133.3 pg/ml, S4: 44.4 pg/ml, S5: 14.8 pg/ml, S6: 4.9 pg/ml, and S7: 1.6 pg/ml.

concentrations as they were normalized for. Following sequential extraction using PBS,
triton and guanidine buffers, a total protein assay, BCA, was ran for each buffer. The BCA plate
layout for all three of the plates is depicted in Figure 15.
Total protein concentrations are listed in Table 9. The range for PBS concentrations was
from 1.4 mg/ml to 5.1 mg/ml, but without the 5.1 mg/ml concentration the range became 1.4
mg/ml to 3.9 mg/ml. The range for triton concentrations was from 2.1 mg/ml to 3.8 mg/ml, and
the range for guanidine concentrations was from 1.3 mg/ml to 3.7 mg/ml. However, if the 3.7
mg/ml data point is excluded, the range condensed to 1.3 mg/ml to 2.8 mg/ml. Between the three
different buffers, looking at the same sample, seem to match up; that is, the samples with values
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Table 7: Analysis of Aβ40 Standard Practice Curves in Triplicate #2
Standard Deviation
within Samples

Average
Concentration
(pg/ml)

Standard Deviation
between Calculated and
Average Values

1

N/A*

N/A*

N/A*

2

0.56

380.68

13.66

3

6.74

138.69

3.79

4

1.01

36.55

5.58

5

1.09

9.47

3.78

6

3.34

6.64

1.21

7

1.19

8.92

5.14

1

N/A*

N/A*

N/A*

2

N/A*

401.72

1.22

3

5.47

155.61

15.75

4

2.35

38.88

3.94

5

15.17

17.39

1.82

6

0.49

3.71

0.87

7

0.66

3.32

1.18

1

N/A*

N/A*

1200

2

22.90

316.46

400

3

8.24

109.02

133.3

4

0.12

25.29

44.4

5

0.30

6.46

14.8

6

0.89

3.65

4.9

7

0.94

5.17

1.6

Standard Number
Curve 1

Curve 2

Curve 3

*

No data for this standard was available.

on the higher end of the PBS range tend to have higher values when compared to the
ranges for the other two buffers as well.
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Figure 14: Comparison of Experimental and Calculated Amyloid Standard Concentrations of Aβ40
Standard Practice Curves in Triplicate #2
Calculated concentrations of the standard curve were compared to the actual values. Calculated values
are shown in blue with a R2 of 1, while the experimental values are shown in orange for curve 1, grey for
curve 2 and yellow for curve 3. R2 were 0.88, 0.97 and 0.89, respectively. The calculated standard
concentrations were as follows: B: 0 pg/ml, S1: 1200 pg/ml, S2: 400 pg/ml, S3: 133.3 pg/ml, S4: 44.4
pg/ml, S5: 14.8 pg/ml, S6: 4.9 pg/ml, and S7: 1.6 pg/ml.

After the BCA was complete, ELISAs were ran on the samples for both A40 and A42. Both the
curve and the samples were loaded in duplicated, and the plate layout is shown in Figure 15. The
normalized sample concentrations average for each duplicate pair are documented in Table 10.
Within each sample, across all buffers and isoforms, values correspond tightly.
Samples 1, 4 and 6 had low values of both A isoforms within the PBS and triton
fractions and no insoluble (guanidine fraction) A in either isoform. Sample 3, 7, 8, and 9 had
low values of both isoforms within the PBS and triton fractions; however, there were
discrepancies between the isoforms in the guanidine fraction. These samples had no A42
concentration for the guanidine value, but showed low levels in the A4o isoform. Sample 2 had
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low levels across all buffers for both isoforms. Sample 10 had high levels of both
isoforms in the PBS fraction, but did not match up between the isoforms for the other two
buffers. For A40, all three buffers produced high concentration values; but, for A42 the triton
value was in the middle of the range, and the guanidine value was 0.00. All other samples (5, and
11-16) had relatively high levels across all buffers for both isoforms. Table 11 shows the
averages for both wild type and APP mice, as well as the standard deviation within the groups.
All APP averages were higher than WT animals (Table 11). For a clear view on the similarity of
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the samples within their respective groups, coefficient of variation (CV) was found
(Table 11). Most CV’s were fairly low, with the exception of the guanidine fraction for both
isoforms in the WT mice. With the exception of the guanidine fractions, WT mice had lower CV
between like samples than APP mice.
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Citrate Synthase Analysis
Citrate synthase activity within the solei muscles of each mouse were analyzed. Each
sample was ran in triplicate, and the average of the three activity values was included in its
respective group. Averages for each mouse as well as for each group are depicted in Figure 16.
There was no significant difference in enzyme activity between the averages of the sedentary and
exercise trained groups.

Table 9: Total Protein Concentrations of APP/WT Mouse Samples
Protein Concentration (mg/ml)
Sample ID
PBS

Triton

Guanidine

1: WT M5

2.0

2.1

1.3

2: WT M6

2.9

3.0

2.2

3: WT M7

3.3

2.7

1.9

4: WT M8

3.1

3.7

3.7

6: WT 8117

3.4

3.4

1.6

7: WT 8104

3.1

3.0

2.3

8: WT 8100

3.9

3.6

2.3

9: WT 8099

5.1

3.2

2.3

5: APP 11141-6

3.1

3.6

2.3

10: APP 11369-6

3.1

2.5

2.1

11: APP 11373-9

1.4

3.8

2.7

12: APP 11370-1

1.8

3.1

2.7

13: APP 10945-5

2.4

2.8

2.7

14: APP 11094-5

2.3

2.5

2.4

15: APP 11085-2

3.5

2.8

2.0

16: APP 11091-8

2.8

3.1

2.8
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Amyloid Beta Analysis
Amyloid levels in the left hippocampus for each sample were analyzed at Washington University
by Dr. John Cirrito’s lab using an ELISA. After the serial extraction, the guanidine and triton
fractions were analyzed for both A40 and A42 levels.
Within the guanidine fraction of the hippocampus, exercise training significantly
decreased the amount of A40 (p = 0.0047) and A42 (p=0.0024) for the chronically stressed
group (Figure 17 A-B). For the socially housed mice, exercise did not significantly decrease the
amount of either hippocampal A isoform compared to the sedentary controls. When comparing
values across housing groups, there was no difference in A levels for the exercise groups.
However, for the sedentary groups, the socially housed animals have significantly lower A42
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levels (p= 0.0009). For the triton fraction, there was no significant difference across any
combination of groups (Figure 17 C-D).
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Figure 16. Citrate synthase activity in
sedentary and exercised groups.

A

B

C

D

Figure 17. Hippocampal amyloid beta concentrations in social and isolated mice.
A) Insoluble Aβ40 concentrations. B) Insoluble Aβ42 concentrations. C) Soluble Aβ40
concentrations. D)Soluble Aβ40 concentrations.
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DISCUSSION

Standard Curve Practice
Single Practice Curve. Generally, the expected outcome of a decreasing trend was
reached (Table 3 and Figure 10), but techniques need additional practice. Standard 1 had to be
masked across all duplicate pairs because the value was well above the expected value for the
curve (Table 2-3). This is normal for the laboratory, and the aim is to get a 5-6-point curve.
This could be corrected by making sure to get the appropriate amount of A to start the curve.
While the concentration values for the blanks is noted as <0.00, the absorbance value was
slightly higher than the lab's background goal of .01 absorbance. This can be corrected with
increased speed, and keeping samples on ice more consistently. Also, standard 5 seems to
have a lower than expected concentration throughout all of the duplicate pairs (Table 2). This
could be due to improper mixing techniques. One of the data points within standard 6 was an
order of magnitude larger than all of the others. This is likely due to improper mixing or
contamination from another well when loading. The <0.00 value of standard 7 in the later
duplicate pairs is normal as standard 7 has such a small concentration of A it typically has a
value similar to the background value. While the variance is not abnormally high, it could
definitely be improved by more accurate pipetting and mixing. The experimental curve had a
R2 value of .7843, which is not considered accurate or successful.
Moving forward, the aliquots of Aβ need to be centrifuged to collect sample at the
bottom of the tube for more accurate pipetting. Also, once Aβ is added to the formic acid,
then the tube needs to be vortexed to properly mix.
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Triple Practice Curves I. As none of the three curves plated demonstrated a
decreasing trend, the outcome was unexpected (Table 5, Figure 12). It is likely that the
reasons for varying and nondecreasing amyloid levels throughout the triplicate groups of each
curve is because of an issue with preparing the curve to be loaded (day 2). If the samples did
not get mixed well a disproportionate amount of amyloid could be placed into a standard
further down the curve. As for curve 2, with hardly any signal, it seems as if very little
amyloid was ever added to the curve (Table 4). This could be due to disruption of the amyloid
within the sample tube. Centrifuging the tube longer prior to pipetting from it could be used to
correct this. All standards exhibited abnormally high standard deviations, indicating
inconsistent pipetting when adding A and mixing.
Triple Practice Curves II. As expected, with the exception of standard 7 in curve 1 and
3, a general decrease in concentration is seem within these samples (Table 7 and Figure 14).
Background was low and close to typical backgrounds of more experienced lab technicians.
Across all curves, standard 1 had to be masked (Table 6). Although this is typical, it could be
because too much amyloid is entering the curve due to underwhelming mixing of the formic acid
and amyloid beta, or due to antibody concentrations. This reasoning is also supported by the
three values of standard 2 that are also over the top of the curve. Overall, Dr. Cirrito believes that
formic acids and amyloid should be combined and then vortexed to ensure proper incorporation.
Across all curves, standard 6 and 7 seem to be close to the background, which is also normal
within the lab. Within each standard, variance is lower than any other set of curves that had been
ran, showing improvement. These can be further improved by increasing mixing of the formic
acid and amyloid as well. Overall, these three curves turned out well enough to proceed with the
project.
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WT/APP Practice Mice
All weights are similar to one another, with only one being slightly below the expected
range of 20-45 g (Table 8). Overall mouse body masses are not available, so it cannot be
determined whether this mouse has a smaller cerebellum due to a smaller overall body size, or
whether there was a possible error during dissection. This indicates that the correct tissues were
harvested and being analyzed.
For the total protein assay, expected averages are as follows: PBS- 3.8-4.2 mg/ml, Triton4.6-5 mg/ml, and Guanidine- 2.8-3.2 mg/ml. The concentrations in Table 9 are mostly lower than
the expected; however, given the age (2+ years) and genotype of these mice the decreased
total protein is expected, making the result expected. These animals exhibited normal total
protein concentrations for their age and genotype, which allowed for normalization of A
concentrations between all animals.
Reasonable concentrations of both amyloid isoforms were found with few exceptions. It
is expected that WT mice would have small amounts of amyloid, nearing 0 in the guanidine
(insoluble) fraction. APP mice should exhibit larger amounts of amyloid and at 2+ years of age,
should have large amounts of insoluble amyloid (guanidine fraction). For amyloid beta 40,
samples 7, 8, 9, 2 and 3 seem to have surprisingly high guanidine amyloid (Table 10). This
could be due to a number of things, including, but not limited to, contamination, or improper
blocking. For amyloid beta 42, sample 2 also has an abnormally high guanidine amyloid level,
and sample 10 seems to be lacking any guanidine amyloid which is unexpected (Table 10). The
discrepancy with sample 2 could be due to contamination or improper blocking, and the
discrepancy with sample 10 indicates that the well was missed upon loading samples, or was
loaded with too small of a volume. These discrepancies match with notable increases in CV for
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those sample groups (Table 11). Overall, the average amyloid values for APP animals are
higher than the WT animals (Table 11), which is expected and indicates a successful ELISA
run beginning with sequential extraction through the actual ELISA. With the averages, and
relatively low CV values (Table 11), this technique is considered mastered, and the protocol is
optimized, allowing for confident analysis of A in actual samples.

Citrate Synthase Analysis
As there was no significant difference in citrate synthase activity between the exercise
and sedentary group, it does not appear that the exercise regimen resulted in a training effect.
This could be due to a multitude of reasons including subthreshold intensity, or lack of proper
exercising by the animals. It is unlikely that the planned exercise training regimen (20 m/min, 60
min/day, 5 days/week for 10 weeks) was subthreshold as previous literature has shown an
exercise training effect with a shorter, less intense regimen in similarly aged mice (Yuede et al.,
2018). Notes taken throughout the treatment for each mouse point to improper execution of the
exercise regimen. For some animals, speed was reduced due to inability to maintain running for
60 minutes at 20m/min. Some animals spent prolonged time on the shockers placed at the end of
the treadmill, which could lead to increased stress. With a lack of an exercise training effect, it is
impossible to reasonably conclude how exercise training may overcome stress in the pathology
of AD.

Amyloid Beta Analysis
Although the exercise training regimen was not successful in producing a training
effect, the exercise the mice did receive was enough to rescue the effects of chronic stress on
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amyloid beta levels in the guanidine fraction. The guanidine fraction is typically used to
measure plaque deposition or vesicular levels of amyloid peptides. As these mice were
sacrificed at 6 months of age, it is possible for the guanidine fraction to represent both pools of
A. Reduction of both A isoforms with exercised for the stressed mice supports past claims
that exercise reduces A (Moore et al., 2016). However, contradictory to past research, the
exercise treatment did not reduce A levels of socially housed mice. This can be attested to the
lack of exercise training that occurred. For A42, in the guanidine-extracted fraction, there is a
housing effect. Sedentary mice that were housed socially had significantly less A42 than
chronically isolated mice. This demonstrates that stress can increase amyloid beta, and that this
increase can potentially be rescued with increased exercise. To confirm these trends, more
research, where a training effect is observed, is necessary. The triton-extracted fraction showed
no difference in amyloid levels between any of the groups. This too can be attested to the lack
of exercise training the animals received. While the physical activity these mice endured was
enough to see comparative benefits between some groups, it is known that exercise is effective
to decrease A in a dose-dependent manner (Moore et al., 2016; Thomas et al., 2020). This
means that repeating this experiment with stricter guidelines for following the high intensity
exercise regimen could yield more conclusive results.
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INTENDED METHODS

Due to the onset of the COVID-19 pandemic, the original goals of this experiment had
to be severely modified. All research beside completion of the exercise training regimen and
tissue collection for mice that had already begun the treatment had to cease with lab and
campus wide closures. With the delay of research, many analytes that were of heavy interest
originally had to be reevaluated.
Initially, many analytes other than the ones previously discuss were going to be
measured to confirm treatment and to investigate the complex relationships between stress,
exercise, the serotonergic system and AD pathology. To confirm that the chronic isolation
treatment provoked stress as intended, CRF and CRFR1 levels in the cortex and hippocampus
were going to be analyzed via western blotting. As a marker of overall brain health, BDNF was
also going to be investigated. BDNF can upregulated by physical activity, and therefore could
be used to link the exercise training regimen to slowed progression of the AD pathology
(Chapman et al., 2013; Thomas et al., 2020).
To assess the serotonergic system under the conditions and treatments explored in this
experiment, serotonin and its receptors were going to be measured. As serotonin is a relatively
small neurotransmitter that is hard to directly analyze. In order to get an idea of 5HT levels,
tryptophan hydrolase, the key enzyme required for 5HT synthesis would have been assayed for
via western blotting. Serotonin receptors 4, 6 and 7 were also going to be analyzed due to
previous literature linking those receptors to decreases in A via decreased production (Fischer
et al., 2016). By knowing these levels more insight about the modulation of AD pathology due
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to serotonergic system could be gained, as well as some insight on the influence of exercise
training on serotonin levels.
All of these intended tests would have shed additional light on the complex
relationships between stress and exercise, and the effects they have on the serotonergic system
and AD pathology. However, with the lack of a training effect, results of these test might have
been inconclusive as well.
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SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS

This study aimed to identify the effect of an exercise training regimen and isolation
stress on serotonin levels in the cortex and the hippocampus, to investigate a possible
correlation in serotonin and A levels following treatment, and to explore the relationship
between BDNF, CRF and serotonin levels. Due to the lack of an exercise training effect and the
delays in research due to COVID-19, none of these goals were achieved. This experiment
confirmed past findings such as the effect of stress on A levels (Dong & Csernansky, 2009;
Green et al., 2006). Interestingly, this experiment also showed that there is potential for
physical activity to be able to rescue the effects stress on A levels.
This experiment should be recreated, with stricter guidelines for following the exercise
training regimen. Past research has shown that 15m/min is above the intensity threshold needed
to elicit a training effect from APP/PS1 mice (Yuede et al., 2018), so potentially lowering the
speed of the treadmills would increase the likelihood of mice to run for the whole treatment.
The intended methods for this experiment should be completed after an exercise training effect
is found to achieve the goals outlined in this experiment and to illuminate these important
relationships.
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